LEADS BIOLABS’ OPAMTISTOMIG (PD-L1/4-1BB BISPECIFIC ANTIBODY) PHASE II CLINICAL STUDY FOR FIRST-LINE TREATMENT OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA ADVANCES TO EXPANSION STAGE

Reuters · 2d ago

Please log in to view news